Ki-67 quantitative evaluation as a marker of cervical intraepithelial neoplasia and human papillomavirus infection

International Journal of Gynecological Cancer

Volumn 20, Issue 1, 2010, Pages 116-119

  Mimica, Marko ^a   Tomić, Snježana ^b   Kardum, Goran ^c   Hofman, Irena Drmić ^b   Kaliterna, Vanja ^d   Pejković, Lidija ^e  

^a Gynenova Policlinic   (Croatia)

^b UNIVERSITY HOSPITAL SPLIT   (Croatia)

^c UNIVERSITY OF SPLIT   (Croatia)

^d Educational Public Health Institute of Split and Dalmatia County   (Croatia)

^e Private Practice   (Croatia)

Author keywords

Cervix; CIN; HPV; Immunohistochemistry; Ki 67

Indexed keywords

BIOLOGICAL MARKER; KI 67 ANTIGEN;

ARTICLE; BASEMENT MEMBRANE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CONDYLOMA ACUMINATUM; CONTROLLED STUDY; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; DISEASE SEVERITY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; INFECTION RISK; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SEROLOGY; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; UTERINE CERVIX EPITHELIUM; VAGINAL HYSTERECTOMY; VIRUS DETECTION; VIRUS TYPING; WART VIRUS;

CASE-CONTROL STUDIES; CERVICAL INTRAEPITHELIAL NEOPLASIA; DNA, VIRAL; FEMALE; GENOTYPE; HUMANS; KI-67 ANTIGEN; MALE; NEOPLASM STAGING; PAPILLOMAVIRUS INFECTIONS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL NEOPLASMS;

EID: 74249113369     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/IGC.0b013e3181bc8da7     Document Type: Article

References (18)

1. Heatley MK. How should we grade CIN? Histopathology. 2002;40:377-390.
2. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189:12-19.
3. Bosch FX, Manos MM, Munoz N, et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International Biological Study on Cervical Cancer (IBSCC) Study Group. J Natl Cancer Inst. 1995;87:796-802.
4. Klaes R, Benner A, Friedrich T, et al. p16INK4a immunohistochemistry improves interobserver agreement in the diagnosis of cervical intraepithelial neoplasia. Am J Surg Pathol. 2002;26:1389-1399.
5. Agoff SN, Lin P, Morihara J, et al. p16(INK4a) expression correlates with degree of cervical neoplasia: a comparison with Ki-67 expression and detection of high-risk HPV types. Mod Pathol. 2003;16:665-673.
6. Türkçüoǧlu I, Tezcan S, Kaygusuz G, et al. The role of p53, Bcl-2 and Ki-67 in premalignant cervical lesions and cervical cancer. Eur J Gynaecol Oncol. 2007;28:290-293.
7. Keating JT, Cviko A, Riethdorf S, et al. Ki-67, Cyclin E, and p16ink4 are complimentary surrogate biomarkers for human papillomavirus-related cervical neoplasia. Am J Surg Pathol. 2001;25:884-891.
8. Kruse AJ, Baak JPA, Helliesen T, et al. Evaluation of MIB-1-positive cell clusters as a diagnostic marker for cervical intraepithelial neoplasia. Am J Surg Pathol. 2002;26:1501-1507.
9. Zanotti S, Fisseler-Eckhoff A, Mannherz HG. Changes in the topological expression of markers of differentiation and apoptosis in defined stages of human cervical dysplasia and carcinoma. Gynecol Oncol. 2003;89:376-384.
10. Looi ML, Dali AZ, Ali SA, et al. Expression of p53, bcl-2 and Ki-67 in cervical intraepithelial neoplasia and invasive squamous cell carcinoma of the uterine cervix. Anal Quant Cytol Histol. 2008;30:63-70.
11. Lorenzato M, Caudroy S, Bronner C, et al. Cell cycle and/or proliferation markers: what is the best method to discriminate cervical high-grade lesions? Hum Pathol. 2005;36:1101-1107.
12. Nobbenhuis MA, Walboomers JM, Helmerhorst TJ, et al. Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study. Lancet. 1999;354:20-25.
13. Bosch FX, Lorincz A, Munoz N, et al. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol. 2002;55:244-265. (Pubitemid 34293391)
14. Kruse AJ, Baak JPA, de Bruin PC, et al. Relationship between the presence of oncogenic HPV DNA assessed by polymerase chain reaction and Ki-67 immunoquantitative features in cervical intraepithelial neoplasia. J Pathol. 2001;195:557-562.
15. Kruse AJ, Baak JPA, de Bruin PC, et al. Ki-67 immunoquantitation in cervical intraepithelial neoplasia (CIN): a sensitive marker for grading. J Pathol. 2001;193:48-54.
16. Baak JP, Kruse AJ, Robboy SJ, et al. Dynamic behavioural interpretation of cervical intraepithelial neoplasia with molecular biomarkers. J Clin Pathol. 2006;59:1017-1028.
17. Kruse AJ, Gudlaugsson E, Helliesen T, et al. Evaluation of prospective, routine application of Ki-67 immunoquantitation in early CIN for assessment of short-term progression risk. Anal Quant Cytol Histol. 2004;26:134-140.
18. Kruse AJ, Baak JP, Janssen EA, et al. Ki67 predicts progression in early CIN: validation of a multivariate progression-risk model. Cell Oncol. 2004;26:13-20.